BioLamina’s vision is to become the global leader in primary cell culture tools ultimately enabling life saving therapies

February 16, 2016 Guest Contributor

Kristian Tryggvason_Biolamina

“We founded BioLamina six years ago and started this journey with just an old computer and a mobile phone.” – Tryggvason

Guest post by Dr. Kristian Tryggvason, Founder and CEO of BioLamina AB

 

BioLamina manufactures and sells high quality primary cell culture reagents based on human recombinant laminins. One of the products, LN-521 (human recombinant laminin-521) has been shown to solve many of the technical problems that have prevented development of human embryonic stem (hES) or induced pluripotent stem (iPS) cell-based therapies. Data is continuously being published in a long line of highly ranked scientific journals including several Nature-group papers. The goal is to make the BioLamina laminins the global standard to culture and differentiate stem cells both in research applications, drug discovery and regenerative medicine. We already sell our products in over 33 countries, both directly and through distributors.

 

We founded BioLamina six years ago and started this journey with just an old computer and a mobile phone. We knocked on doors to sell our products to the leading stem cell scientists around the world. Our hard work has been a success; today we are a company with 14 employees including production, product development, logistics, sales and marketing, and our products have become so sought after that the three leading companies within primary cell culture reagents, ThermoFisher Scientific, Corning and Stem Cell Technologies, have included BioLamina’s LN-521 as a high-end stem cell matrix in their product portfolios.

 

The reason for the increasing demand of laminins is rock solid science behind the products and the functional advantage of laminins compared to older generations of stem cell matrices. BioLamina laminins are the only original full-length, recombinant laminins on the market. By mimicking the natural niche in the dish they replace nature’s own laminins and thus we offer a new generation of biologically relevant tools for primary stem cell culture.

 

BioLamina’s approach has, already from the start, been to help scientists solve their problems, always in a very consultative and collaborative way. We are continuing our globalization with the help of our new recent partners as we are taking one step at a time to revolutionize cell culture and become recognized as the leading provider of tools for primary cell culture to enable life saving therapies.

 

Meet Tryggvason and executives from other exciting Swedish-based companies at BIO-Europe Spring® in Stockholm Sweden April 4–6, 2016.

Read more...

Previous Article
Still unsure about China? FT article highlights rise in China pharma R&D, innovation
Still unsure about China? FT article highlights rise in China pharma R&D, innovation

What is China’s real potential for R&D and innovative “breakthrough” products? February 18 article by Andre...

Next Article
Top 10 Digital Health Trends: Implications for Early to Mid-Stage Biopharma
Top 10 Digital Health Trends: Implications for Early to Mid-Stage Biopharma

Guest post by Jay Goldman (Managing Director, Sensei Labs at Klick Health) and Michael W. Young (VP, Strate...